| P2093 | author name string | Ruli Gao | |
| | Yuanqing Yan | |
| | Maria Bartolomeo Grant | |
| | Thao L P Trinh | |
| P2860 | cites work | Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection | Q39983492 |
| | METABOLOMICS DIFFERENTIAL CORRELATION NETWORK ANALYSIS OF OSTEOARTHRITIS. | Q40098533 |
| | Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause? | Q40282977 |
| | The pancreatic cancer cell line MIA PaCa2 produces one or more factors able to induce hyperglycemia in SCID mice. | Q41274113 |
| | Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma | Q43824212 |
| | Type 2 diabetes mellitus and survival in pancreatic adenocarcinoma: a retrospective cohort study | Q44749291 |
| | Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. | Q50561038 |
| | Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. | Q50885033 |
| | Serum thyroglobulin concentration in patients with diabetes mellitus. | Q51628991 |
| | Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor? | Q54252640 |
| | Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients. | Q54397804 |
| | Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles. | Q54422958 |
| | Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma | Q56899396 |
| | The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells | Q56902123 |
| | Diabetes and the Risk of Pancreatic Cancer | Q60023737 |
| | Impact of diabetes mellitus on outcomes in patients with colon cancer | Q78863604 |
| | Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 |
| | Natural selection of tumor variants in the generation of "tumor escape" phenotypes | Q24551158 |
| | Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes | Q24595981 |
| | New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer | Q24656132 |
| | Diabetes and cancer: a consensus report. | Q27686977 |
| | edgeR: a Bioconductor package for differential expression analysis of digital gene expression data | Q27860819 |
| | The blockade of immune checkpoints in cancer immunotherapy | Q27860852 |
| | Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 |
| | PD-1 and its ligands in tolerance and immunity | Q28131650 |
| | Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies | Q28175267 |
| | Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor | Q28251328 |
| | TCGA-assembler: open-source software for retrieving and processing TCGA data | Q30827501 |
| | Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation | Q33887648 |
| | Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205 | Q34049250 |
| | Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer | Q34387974 |
| | Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis | Q34722287 |
| | Current immunotherapeutic approaches in pancreatic cancer. | Q35212837 |
| | GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers | Q35557782 |
| | Impact of diabetes mellitus on clinical outcomes in patients undergoing surgical resection for pancreatic cancer: a retrospective, cohort study. | Q35771246 |
| | TCGA2STAT: simple TCGA data access for integrated statistical analysis in R. | Q35841457 |
| | Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy | Q35886496 |
| | Whole genomes redefine the mutational landscape of pancreatic cancer | Q35911034 |
| | Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays | Q36802303 |
| | Prognostic value of PDL1 expression in pancreatic cancer | Q37687595 |
| | Diabetes and pancreatic cancer: chicken or egg? | Q37853809 |
| | Immune Therapy in GI Malignancies: A Review | Q38445709 |
| | Targeting of IL-4 and IL-13 receptors for cancer therapy | Q38531637 |
| | Immunotherapy for pancreatic cancer | Q38722325 |
| | Current standards and new innovative approaches for treatment of pancreatic cancer. | Q38724803 |
| | RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4 | Q38765467 |
| | Genomic analyses identify molecular subtypes of pancreatic cancer | Q38791499 |
| | Cancer Statistics, 2017. | Q39038674 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adenocarcinoma | Q356033 |
| | pancreatic adenocarcinoma | Q18556189 |
| P577 | publication date | 2017-07-06 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics | |